Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash-to-Debt 25.76
ATNX's Cash-to-Debt is ranked lower than
52% of the 1056 Companies
in the Global Biotechnology industry.

( Industry Median: 73.06 vs. ATNX: 25.76 )
Ranked among companies with meaningful Cash-to-Debt only.
ATNX' s Cash-to-Debt Range Over the Past 10 Years
Min: 1.27  Med: 15.28 Max: 25.76
Current: 25.76
1.27
25.76
Equity-to-Asset 0.64
ATNX's Equity-to-Asset is ranked higher than
60% of the 770 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. ATNX: 0.64 )
Ranked among companies with meaningful Equity-to-Asset only.
ATNX' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.32  Med: 0.64 Max: 0.81
Current: 0.64
0.32
0.81
Debt-to-Equity 0.02
ATNX's Debt-to-Equity is ranked higher than
89% of the 488 Companies
in the Global Biotechnology industry.

( Industry Median: 0.27 vs. ATNX: 0.02 )
Ranked among companies with meaningful Debt-to-Equity only.
ATNX' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.02  Med: 0.04 Max: 0.98
Current: 0.02
0.02
0.98
Debt-to-EBITDA -0.02
ATNX's Debt-to-EBITDA is ranked lower than
99.99% of the 213 Companies
in the Global Biotechnology industry.

( Industry Median: 1.97 vs. ATNX: -0.02 )
Ranked among companies with meaningful Debt-to-EBITDA only.
ATNX' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.39  Med: -0.07 Max: -0.02
Current: -0.02
-0.39
-0.02
Piotroski F-Score: 5
Altman Z-Score: 7.26
Beneish M-Score: -3.29
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating Margin % -289.11
ATNX's Operating Margin % is ranked lower than
68% of the 800 Companies
in the Global Biotechnology industry.

( Industry Median: -98.02 vs. ATNX: -289.11 )
Ranked among companies with meaningful Operating Margin % only.
ATNX' s Operating Margin % Range Over the Past 10 Years
Min: -417.24  Med: -363.65 Max: -289.11
Current: -289.11
-417.24
-289.11
Net Margin % -344.79
ATNX's Net Margin % is ranked lower than
70% of the 800 Companies
in the Global Biotechnology industry.

( Industry Median: -88.19 vs. ATNX: -344.79 )
Ranked among companies with meaningful Net Margin % only.
ATNX' s Net Margin % Range Over the Past 10 Years
Min: -426.82  Med: -362.88 Max: -344.79
Current: -344.79
-426.82
-344.79
ROE % -165.14
ATNX's ROE % is ranked lower than
92% of the 969 Companies
in the Global Biotechnology industry.

( Industry Median: -40.23 vs. ATNX: -165.14 )
Ranked among companies with meaningful ROE % only.
ATNX' s ROE % Range Over the Past 10 Years
Min: -211.83  Med: -133.54 Max: -51.87
Current: -165.14
-211.83
-51.87
ROA % -100.38
ATNX's ROA % is ranked lower than
90% of the 1062 Companies
in the Global Biotechnology industry.

( Industry Median: -32.55 vs. ATNX: -100.38 )
Ranked among companies with meaningful ROA % only.
ATNX' s ROA % Range Over the Past 10 Years
Min: -106.51  Med: -77.51 Max: -42.02
Current: -100.38
-106.51
-42.02
ROC (Joel Greenblatt) % -1504.60
ATNX's ROC (Joel Greenblatt) % is ranked lower than
73% of the 1021 Companies
in the Global Biotechnology industry.

( Industry Median: -430.94 vs. ATNX: -1504.60 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
ATNX' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -1622.13  Med: -1426.23 Max: -806.3
Current: -1504.6
-1622.13
-806.3
GuruFocus has detected 4 Warning Signs with Athenex Inc ATNX.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» ATNX's 30-Y Financials

Financials (Next Earnings Date: 2018-08-14)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

ATNX Guru Trades in

ATNX Guru Trades in

Q2 2017

ATNX Guru Trades in Q2 2017

Paul Tudor Jones 20,000 sh (New)
» More
Q3 2017

ATNX Guru Trades in Q3 2017

Paul Tudor Jones Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with NAS:ATNX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Athenex Inc does not have enough historical financial data to display Peter Lynch Chart.

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:MRTX, SZSE:000518, SHSE:603896, NAS:RGNX, HKSE:01681, SAU:2070, SZSE:300149, NAS:GERN, NYSE:BHVN, SZSE:002872, SZSE:300255, NAS:AMRN, XPAR:GNFT, XKRX:102940, SZSE:300204, NAS:NTLA, XKRX:078160, HKSE:06826, SZSE:002022, SZSE:300147 » details
Traded in other countries:2MT.Germany,
Headquarter Location:USA
Athenex Inc is a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer.

Athenex Inc is a global biopharmaceutical company. It is dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer. The company's mission is to improve the lives of cancer patients by creating more effective, safer and tolerable treatments. The company has organized its business model into three segments, Oncology Innovation Platform, Commercial Platform and Global Supply Chain Platform with operations in both the U.S. and China.

Top Ranked Articles about Athenex Inc

Athenex, Inc. Receives U.S. FDA Orphan Drug Designation for Oraxol for the Treatment of Angiosarcoma
Report: Exploring Fundamental Drivers Behind Exponent, Monotype Imaging, Athenex, State Street, Heartland Financial, and IRSA Inversiones Y Representaciones S.A — New Horizons, Emerging Trends, and Upcoming Developments
Weekly CEO Buys Highlight CEO buys included the following companies: OPKO Health, Schlumberger, Enterprise Products Partners, Athenex and Encana
According to GuruFocus Insider Data, these are the largest CEO buys during the past week. Read more...
Report: Developing Opportunities within Retail Properties of America, State Street, Potbelly, Nanometrics, Athenex, and Senior Housing Properties Trust — Future Expectations, Projections Moving into 2018
Athenex to Present at the 17th Annual Needham Healthcare Conference
Athenex Announces Phase II Clinical Study Results for KX2-391 Ointment for the Treatment of Actinic Keratosis in the American Academy of Dermatology Meeting
Athenex to Present at 2018 RBC Capital Markets Healthcare Conference
Athenex實現轉移性乳腺癌三期臨床試驗受試者招募目標,計劃在2018年第三季度進行第二次中期分析
Athenex Meets Enrollment Target for Oraxol Phase III Clinical Trial in Metastatic Breast Cancer
Athenex Announces Early Completion of Patients Enrollment for Two Phase III Clinical Studies of KX2-391 Ointment for Actinic Keratosis

Ratios

vs
industry
vs
history
PB Ratio 10.60
ATNX's PB Ratio is ranked lower than
73% of the 954 Companies
in the Global Biotechnology industry.

( Industry Median: 4.51 vs. ATNX: 10.60 )
Ranked among companies with meaningful PB Ratio only.
ATNX' s PB Ratio Range Over the Past 10 Years
Min: 6.42  Med: 9.12 Max: 11.33
Current: 10.6
6.42
11.33
PS Ratio 23.13
ATNX's PS Ratio is ranked lower than
67% of the 733 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. ATNX: 23.13 )
Ranked among companies with meaningful PS Ratio only.
ATNX' s PS Ratio Range Over the Past 10 Years
Min: 20.03  Med: 29.48 Max: 57.91
Current: 23.13
20.03
57.91
EV-to-EBIT -8.13
ATNX's EV-to-EBIT is ranked lower than
99.99% of the 262 Companies
in the Global Biotechnology industry.

( Industry Median: 24.43 vs. ATNX: -8.13 )
Ranked among companies with meaningful EV-to-EBIT only.
ATNX' s EV-to-EBIT Range Over the Past 10 Years
Min: -8.74  Med: -7.1 Max: -4
Current: -8.13
-8.74
-4
EV-to-EBITDA -8.41
ATNX's EV-to-EBITDA is ranked lower than
99.99% of the 287 Companies
in the Global Biotechnology industry.

( Industry Median: 21.70 vs. ATNX: -8.41 )
Ranked among companies with meaningful EV-to-EBITDA only.
ATNX' s EV-to-EBITDA Range Over the Past 10 Years
Min: -9.02  Med: -7.3 Max: -4.1
Current: -8.41
-9.02
-4.1
EV-to-Revenue 25.96
ATNX's EV-to-Revenue is ranked lower than
64% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: 13.46 vs. ATNX: 25.96 )
Ranked among companies with meaningful EV-to-Revenue only.
ATNX' s EV-to-Revenue Range Over the Past 10 Years
Min: 20.3  Med: 28 Max: 37.5
Current: 25.96
20.3
37.5
Current Ratio 1.86
ATNX's Current Ratio is ranked lower than
60% of the 1035 Companies
in the Global Biotechnology industry.

( Industry Median: 4.21 vs. ATNX: 1.86 )
Ranked among companies with meaningful Current Ratio only.
ATNX' s Current Ratio Range Over the Past 10 Years
Min: 1.85  Med: 1.86 Max: 3.7
Current: 1.86
1.85
3.7
Quick Ratio 1.49
ATNX's Quick Ratio is ranked lower than
62% of the 1035 Companies
in the Global Biotechnology industry.

( Industry Median: 3.92 vs. ATNX: 1.49 )
Ranked among companies with meaningful Quick Ratio only.
ATNX' s Quick Ratio Range Over the Past 10 Years
Min: 1.49  Med: 1.7 Max: 3.52
Current: 1.49
1.49
3.52
Days Inventory 141.02
ATNX's Days Inventory is ranked higher than
56% of the 498 Companies
in the Global Biotechnology industry.

( Industry Median: 126.17 vs. ATNX: 141.02 )
Ranked among companies with meaningful Days Inventory only.
ATNX' s Days Inventory Range Over the Past 10 Years
Min: 69.38  Med: 90.36 Max: 151.11
Current: 141.02
69.38
151.11
Days Sales Outstanding 81.25
ATNX's Days Sales Outstanding is ranked lower than
65% of the 656 Companies
in the Global Biotechnology industry.

( Industry Median: 64.11 vs. ATNX: 81.25 )
Ranked among companies with meaningful Days Sales Outstanding only.
ATNX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 49.32  Med: 81.25 Max: 100.31
Current: 81.25
49.32
100.31
Days Payable 242.04
ATNX's Days Payable is ranked higher than
69% of the 456 Companies
in the Global Biotechnology industry.

( Industry Median: 62.86 vs. ATNX: 242.04 )
Ranked among companies with meaningful Days Payable only.
ATNX' s Days Payable Range Over the Past 10 Years
Min: 132.8  Med: 174.02 Max: 242.04
Current: 242.04
132.8
242.04

Buy Back

vs
industry
vs
history

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 1630.00
ATNX's Price-to-Net-Cash is ranked lower than
83% of the 568 Companies
in the Global Biotechnology industry.

( Industry Median: 8.85 vs. ATNX: 1630.00 )
Ranked among companies with meaningful Price-to-Net-Cash only.
ATNX' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 1590  Med: 1590 Max: 1745
Current: 1630
1590
1745
Price-to-Net-Current-Asset-Value 28.60
ATNX's Price-to-Net-Current-Asset-Value is ranked lower than
78% of the 695 Companies
in the Global Biotechnology industry.

( Industry Median: 7.88 vs. ATNX: 28.60 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
ATNX' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 27.89  Med: 27.89 Max: 30.61
Current: 28.6
27.89
30.61
Price-to-Tangible-Book 21.73
ATNX's Price-to-Tangible-Book is ranked lower than
79% of the 874 Companies
in the Global Biotechnology industry.

( Industry Median: 5.88 vs. ATNX: 21.73 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
ATNX' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 21.2  Med: 21.2 Max: 23.27
Current: 21.73
21.2
23.27
Price-to-Median-PS-Value 0.78
ATNX's Price-to-Median-PS-Value is ranked higher than
52% of the 614 Companies
in the Global Biotechnology industry.

( Industry Median: 1.00 vs. ATNX: 0.78 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
ATNX' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.77  Med: 0.77 Max: 0.84
Current: 0.78
0.77
0.84
Earnings Yield (Greenblatt) % -12.27
ATNX's Earnings Yield (Greenblatt) % is ranked lower than
65% of the 1060 Companies
in the Global Biotechnology industry.

( Industry Median: -6.86 vs. ATNX: -12.27 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
ATNX' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -25  Med: -14.1 Max: -11.42
Current: -12.27
-25
-11.42

More Statistics

Revenue (TTM) (Mil) $38.04
EPS (TTM) $ -2.70
52-Week Range $11.21 - 20.79
Shares Outstanding (Mil)63.49

Piotroski F-Score Details

Piotroski F-Score: 55
Positive ROAN
Positive CFROAN
Higher ROA yoyN
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyY
Less Shares Outstanding yoyN
Higher Gross Margin yoyY
Higher Asset Turnover yoyY

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}